APA (7th ed.) Citation

Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., . . . Chiang, V. (2016). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncology, 17(7), 976. https://doi.org/10.1016/S1470-2045(16)30053-5

Chicago Style (17th ed.) Citation

Goldberg, Sarah B., et al. "Pembrolizumab for Patients with Melanoma or Non-small-cell Lung Cancer and Untreated Brain Metastases: Early Analysis of a Non-randomised, Open-label, Phase 2 Trial." Lancet Oncology 17, no. 7 (2016): 976. https://doi.org/10.1016/S1470-2045(16)30053-5.

MLA (9th ed.) Citation

Goldberg, Sarah B., et al. "Pembrolizumab for Patients with Melanoma or Non-small-cell Lung Cancer and Untreated Brain Metastases: Early Analysis of a Non-randomised, Open-label, Phase 2 Trial." Lancet Oncology, vol. 17, no. 7, 2016, p. 976, https://doi.org/10.1016/S1470-2045(16)30053-5.